PTCT News and Press, PTC Therapeutics Inc. From 05/28/24

2024-05-28 09:01:27 ET More on PTC Therapeutics PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts PTC Therapeutics, Inc. (PTCT) Q1 2024 Earnings Call Transcript PTC The...

PTC Therapeutics Announces Validation of Sepiapterin European MAA PR Newswire - Review of European marketing application for PKU now initiated - WARREN, N.J. , May 28, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the sep...

2024-05-22 07:53:10 ET Summary Translarna remains conditionally approved in Europe, despite a negative CHMP opinion and lacking U.S. approval. PTC's diverse pipeline includes potential treatments for PKU and FA, but faces significant commercial challenges. Financial analysis s...

2024-05-20 20:15:01 ET Citigroup analyst issues SELL recommendation for PTCT on May 20, 2024 07:00PM ET. The previous analyst recommendation was Sell. PTCT was trading at $40.12 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...

2024-05-20 18:17:01 ET More on Larimar Therapeutics Seeking Alpha’s Quant Rating on Larimar Therapeutics Historical earnings data for Larimar Therapeutics Financial information for Larimar Therapeutics Read the full article on Seeking Alpha For...

2024-05-20 15:00:04 ET Kelly Shi from Jefferies issued a price target of $46.00 for PTCT on 2024-05-20 12:29:00. The adjusted price target was set to $46.00. At the time of the announcement, PTCT was trading at $39.81. The overall price target consensus is at $43.80 with...

2024-05-20 11:30:02 ET Raymond James analyst issues MARKET PERFORM recommendation for PTCT on May 20, 2024 08:59AM ET. The previous analyst recommendation was Underperform. PTCT was trading at $37.57 at issue of the analyst recommendation. The overall analyst consensus :...

2024-05-20 10:00:26 ET More on Health Care Select Sector SPDR XLV: Healthcare Is Ripe For Buying, Despite Patent Cliff XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care Short interest in S&P 500 ...

2024-05-20 09:58:45 ET More on PTC Therapeutics PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts PTC Therapeutics, Inc. (PTCT) Q1 2024 Earnings Call Transcript PTC Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript PTC Therapeuti...

PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation PR Newswire - European Commission decides against adoption of negative opinion - - Translarna authorization remains active in Europe - - 2024 rev...